Decline in US Drug Overdose Deaths by Region, Substance, and Demographics

Area of Science:

• Public Health Surveillance
• Epidemiology of Drug Overdose
• Health Disparities Research

Background:

• Drug overdose deaths (DODs) in the US have surged, particularly with the rise of fentanyl.
• Standard surveillance systems lack the granularity to capture monthly DOD rate variability and seasonality.
• Accurate, timely data is crucial for understanding overdose trends and informing public health responses.

Purpose of the Study:

• To pinpoint the timing of the deceleration in US DOD rates.
• To analyze patterns in DOD rates by census region, drug type, and demographic factors.
• To assess the recent trends in drug overdose mortality across the United States.

Main Methods:

• A repeated cross-sectional study design was employed, analyzing DOD data from January 2015 to October 2024.
• Data sources included the National Center for Health Statistics and the US Census Bureau.
• Joinpoint regression analysis was used to identify significant shifts in monthly DOD rates, considering drug type, region, and demographics.

Main Results:

• The national DOD rate increased until August 2023, then began a sustained decline, accelerating through October 2024.
• Opioid-related DOD rates declined faster than stimulant-related rates; regional peaks varied, with some areas peaking in late 2022 and others in late 2023.
• By late 2023, DOD rates continued to accelerate among older adults and specific racial/ethnic minority groups, despite an overall slowing pace.

Conclusions:

• US DOD rates entered a new phase of sustained deceleration in 2023, following two decades of increases.
• This shift may be influenced by evolving drug markets, improved treatment access, harm reduction initiatives, and population-level risk factors.
• Persistent disparities underscore the need for targeted interventions and a deeper understanding of the drivers behind these trends.